Introducing HDAC-Targeting Radiopharmaceuticals for Glioblastoma Imaging and Therapy.

Area of Science:

• Oncology
• Molecular Biology
• Radiopharmaceuticals

Background:

• Glioblastoma (GB) remains a challenging brain cancer with poor prognosis despite multimodal treatments.
• Histone deacetylases (HDACs) are emerging targets due to their role in cell proliferation, apoptosis, and DNA repair.
• HDAC inhibitors (HDACi) are investigated as anti-cancer agents, but their therapeutic efficacy in GB requires further definition.

Purpose of the Study:

• To provide a comprehensive review of the current status of HDAC inhibitors in glioblastoma therapy.
• To overview existing HDAC-targeting radiopharmaceuticals for glioblastoma.
• To explore the potential of imaging HDAC expression or activity for patient stratification and therapeutic guidance.

Main Methods:

• Literature review of preclinical and clinical studies on HDAC inhibitors for glioblastoma.
• Survey of current developments in HDAC-targeting radiopharmaceuticals.
• Discussion of the role of HDAC imaging in gliomagenesis and treatment selection.

Main Results:

• HDAC inhibitors exhibit pleiotropic effects relevant to cancer therapy, including DNA repair and cell cycle regulation.
• The therapeutic activity of HDAC inhibitors in glioblastoma is not yet fully elucidated.
• Radiopharmaceuticals targeting HDACs are being developed for imaging and potentially therapeutic applications.

Conclusions:

• HDAC inhibitors represent a promising therapeutic strategy for glioblastoma.
• HDAC-targeting radiopharmaceuticals offer potential for non-invasive assessment of HDAC activity.
• Imaging HDAC expression could identify glioblastoma patients who may benefit from HDAC inhibitor therapy.